

Amendments to the Specification

On page 1, please insert the following new paragraph beginning at line 2:

--This is the U.S. National Stage of International Application No. PCT/GB2004/001572, filed April 7, 2004 (published in English under PCT Article 21(2)), which in turn claims the benefit of Great Britain Patent Application No. 0308088.4, filed April 9, 2003, and Great Britain Patent Application No. 0324235.1, filed October 16, 2003.--

Please replace the paragraphs beginning on line 12 of page 3 with the following re-written paragraphs:

-- In a further preferred embodiment of the invention said domain comprises the amino acid sequence:

PSPTPTETAT PSPTPKPTST PEETEAPSSA TTLISPLSLI VIFISFVLLI (SEQ ID NO: 12).

In an alternative preferred embodiment of the invention said domain comprises the amino acid sequence:

LVPRGSIEGR GTSITAYNSE GESAEFFFL ILLLLVLV (SEQ ID NO: 13).

In a further alternative preferred embodiment of the invention said domain comprises the amino acid sequence:

TSITAYKSE GESAEFFFL ILLLLVLV (SEQ ID NO: 14)--

Please replace the paragraph beginning on line 18 of page 10 with the following re-written paragraph:

--Gly Gly Gly Gly Ser (hereinafter referred to as "Gly4Ser"; SEQ ID NO: 15)--

Please replace the paragraphs beginning on line 27 of page 10 with the following re-written paragraphs:

--Preferably said cleavage site comprises the amino acid sequence: LVPRGS (SEQ ID NO: 16), or variant thereof.

In a further preferred embodiment of the invention said cleavage site comprises at least one copy of the amino acid sequence: SGGGG (SEQ ID NO: 17), or functional variant thereof. Preferably, said cleavage site comprises the amino acid sequence PGISGGGGGG (SEQ ID NO: 18).

More preferably still said cleavage site comprises the amino acid sequence: LVPRGS PGISGGGGGG (SEQ ID NO: 19), or variant thereof.

Alternatively, said cleavage site comprises at least two copies of the amino acid sequence SGGGG (SEQ ID NO: 17), or functional variant thereof, which flank said cleavage site. --

Please replace the paragraphs beginning on line 25 of page 21 with the following re-written paragraphs:

--Figure 2 illustrates the nucleotide (SEQ ID NO: 1) and amino acid sequence (SEQ ID NO: 2) of the GH-GPI construct. Sequence from the original pCR-3/GPI vector is shown underlined, linker sequence between the promoter and the initiation codon, *ATG*, is shown in white on black and the subsequent GHR signal sequence is in *similar colours but italicised*. The GH sequence is shown in CAPITALS and the link between the GH protein and the GPI anchor shown in black on grey, the GPI anchor signal sequence is shown *italicised and underlined*. All the relevant restrictions sites are in **bold** and include *Bam*HI (ggatcc), *Nde*I (catatg) and *Eco*RV (gatatc);

Figure 3 illustrates the nucleotide (SEQ ID NO: 3) and amino acid (SEQ ID NO: 4) sequence of the 1B1-GPI construct (1B1 is GH linked to GHR).

Sequence from the original pCR-3/GPI vector is shown underlined, linker sequence between the promoter and the initiation codon, *ATG*, is shown in white on black and the subsequent GHR signal sequence is shown in *similar colours but italicised*. The 1B1 sequence is shown in

CAPITALS and the link between the 1B1 protein and the GPI anchor shown in black on grey, the GPI anchor signal sequence is shown *italicised and underlined*. All the relevant restrictions sites are in **bold** and include *Bam*HI (ggatcc), *Nde*I (catatg) and *Xma*I (cccggg);

Figure 4 illustrates the nucleotide (SEQ ID NO: 5) and amino acid (SEQ ID NO: 6) sequence of the 1C1-GPI construct (1C1 is GH linked to GH as a tandem).

Sequence from the original pCR-3/GPI vector is shown underlined, linker sequence between the promoter and the initiation codon, *ATG*, is shown in white on black and the subsequent GHR signal sequence is shown in *similar colours but italicised*. The 1C1 sequence is shown in CAPITALS and the link between the 1C1 protein and the GPI anchor shown in black on grey, the GPI anchor signal sequence is shown *italicised and underlined*. All the relevant restrictions sites are in **bold** and include *Bam*HI (ggatcc), *Nde*I (catatg) and *Eco*RV (gatatc); --

Please replace the paragraph beginning on line 25 of page 23 with the following re-written paragraph:

-- The primers GH2GPI_for1 and GH2GPI_rev1 (Table 1; SEQ ID NOS: 7-11) were used in a PCR reaction to amplify the hGH gene flanked by *Nde*I and *Eco*RV sites. The resulting PCR product was digested with these restriction enzymes and then ligated into *Nde*I/*Eco*RV double-digested pCR3-GPI. This was then ligated into *E. coli* XL1 Blue cells.--

Please insert the Abstract, submitted herewith on a separate page, as page 33 at the end of the application.

Please replace the previous sequence listing with pages 1-13 of the enclosed sequence listing.